Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
Ab182763-100μg
|
100μg |
10
|
$109.90
|
|
|
Ab182763-1mg
|
1mg |
4
|
$519.90
|
|
|
Ab182763-5mg
|
5mg |
1
|
$1,399.90
|
|
|
Ab182763-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$2,239.90
|
|
Purity>95% (SDS-PAGE&SEC); Endotoxin Level < 0.01EU/μg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Cofetuzumab (anti-CCK4) - Primary antibody, specific to PTK7, >95% (SDS-PAGE&SEC), high purity, Human IgG1 |
|---|---|
| Synonyms | 8430404F20Rik antibody | CCK 4 antibody | CCK-4 antibody | Colon carcinoma kinase 4 antibody | Human colon carcinoma kinase 4 (CCK4) mRNA complete cds antibody | Inactive tyrosine-protein kinase 7 antibody | mPTK7/CCK4 antibody | OTTHUMP00000217016 antibo |
| Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA |
| Host species | Human |
| Specificity | PTK7 |
| Conjugation | Unconjugated |
| Grade | Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Product Description |
Cofetuzumab (anti-CCK4) is a humanized IgG1-κ monoclonal antibody targeting PTK7. The expression system of Cofetuzumab (anti-CCK4) is usually CHO (Chinese Hamster Ovary) cells. |
| Isotype | Human IgG1 |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 27.1 kDa (Light Chain) & 50.9 kDa (Heavy Chain), under reducing conditions; 197.2 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Purity | >95% (SDS-PAGE&SEC) |
| Shape | Liquid |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle. |
| CAS | 1869928-62-0 |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Cofetuzumab (anti-CCK4) (Ab182763) - Flow Cytometry
Flow Cytometry analysis of MCF-7 cells labelling CCK4 (red) with Cofetuzumab (anti-CCK4) (Ab182763). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Cofetuzumab (anti-CCK4) (Ab182763) - Flow Cytometry
Flow Cytometry analysis of A431 cells labelling CCK4 (red) with Cofetuzumab (anti-CCK4) (Ab182763). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Cofetuzumab (anti-CCK4) (Ab182763) - Flow Cytometry
Flow Cytometry analysis of HeLa cells labelling CCK4 (red) with Cofetuzumab (anti-CCK4) (Ab182763). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Cofetuzumab (anti-CCK4) (Ab182763) - Flow Cytometry
Flow Cytometry analysis of A549 cells labelling CCK4 (red) with Cofetuzumab (anti-CCK4) (Ab182763). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Cofetuzumab (anti-CCK4) (Ab182763) - SEC
The purity of Cofetuzumab (anti-CCK4) (Ab182763) is more than 95% verified by HPLC.
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
| Certificate of Analysis | Jul 04, 2024 | Ab182763 | |
| Certificate of Analysis | Jul 04, 2024 | Ab182763 | |
| Certificate of Analysis | Jul 04, 2024 | Ab182763 |